Company profile for Marengo Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Marengo Therapeutics is pioneering a new way to activate the body’s own immune system to mount a rapid, effective, and durable response against cancer. Our unique therapeutic platform selectively boosts T cells, turbocharging potent anti-tumor activity and promoting long-term immunity to keep cancer at bay. Activating the right immune response to promote lifelong protection against cancer.To create a world in which everyone...
Marengo Therapeutics is pioneering a new way to activate the body’s own immune system to mount a rapid, effective, and durable response against cancer. Our unique therapeutic platform selectively boosts T cells, turbocharging potent anti-tumor activity and promoting long-term immunity to keep cancer at bay. Activating the right immune response to promote lifelong protection against cancer.To create a world in which everyone’s immune system can defeat cancer. Marengo’s lead project, a first- and -best-in-class therapy with single agent potential, is progressing to IND for several solid tumors with high-unmet medical needs.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
840 Memorial Drive, 4th Floor, Cambridge, MA 02139
Telephone
Telephone
(617) 917-4980
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/marengo-to-present-initial-results-from-invikafusp-alfa-and-trodelvy-combination-study-start-002-at-the-2025-san-antonio-breast-cancer-symposium-302639926.html

PR NEWSWIRE BIO
12 Dec 2025

https://www.prnewswire.com/news-releases/marengo-late-breaking-oral-presentation-highlights-single-agent-pan-tumor-activity-of-invikafusp-alfa-across-pd-1-resistant-cancers-in-phase-2-clinical-trial-at-sitc-2025-302607991.html

PR NEWSWIRE
07 Nov 2025

https://www.prnewswire.com/news-releases/marengo-to-present-late-breaking-clinical-oral-abstract-at-sitc-2025-highlighting-initial-monotherapy-activity-of-invikafusp-alfa-in-tissue-agnostic-tmb-high-advanced-cancers-302600621.html

PR NEWSWIRE
31 Oct 2025

https://www.prnewswire.com/news-releases/marengo-presents-initial-phase-2-results-demonstrating-broad-single-agent-activity-of-invikafusp-alfa-across-multiple-pd-1-refractory-or--resistant-solid-tumors-as-a-late-breaking-oral-presentation-at-esmo-2025-302587142.html

PR NEWSWIRE
17 Oct 2025

https://www.prnewswire.com/news-releases/marengo-to-present-a-late-breaking-clinical-oral-abstract-at-esmo-2025-on-initial-phase-2-clinical-data-of-invikafusp-monotherapy-activity-in-patients-with-antigen-rich-solid-tumors-resistant-to-immune-checkpoint-blockade-302565714.html

PR NEWSWIRE
24 Sep 2025

https://www.prnewswire.com/news-releases/marengo-therapeutics-advances-start-002-clinical-trial-into-phase-2-cohort-expansion-evaluating-invikafusp-alfa-with-trop2-directed-adc-trodelvy-in-metastatic-breast-cancer-302559912.html

PR NEWSWIRE
18 Sep 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty